Intellia Therapeutics Future Growth
Future criteria checks 2/6
Intellia Therapeutics is forecast to grow earnings and revenue by 56.4% and 58.7% per annum respectively. EPS is expected to grow by 57.4% per annum. Return on equity is forecast to be 6.6% in 3 years.
Key information
56.4%
Earnings growth rate
57.41%
EPS growth rate
| Biotechs earnings growth | 29.0% |
| Revenue growth rate | 58.7% |
| Future return on equity | 6.64% |
| Analyst coverage | Good |
| Last updated | 09 Sep 2026 |
Recent future growth updates
Analysis Article • Aug 10
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported And Analysts Have Been Cutting Their Estimates
It's been a pretty great week for Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) shareholders, with its shares surging 11...Analysis Article • May 14
Earnings Update: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) defied analyst predictions to release its quarterly results, which were...Analysis Article • May 11
Analysts Have Made A Financial Statement On Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) First-Quarter Report
A week ago, Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) came out with a strong set of first-quarter numbers that could...Analysis Article • Mar 02
Earnings Release: Here's Why Analysts Cut Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Price Target To US$46.08
Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) defied analyst predictions to release its yearly results, which were ahead...Analysis Article • Aug 11
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
The analysts might have been a bit too bullish on Intellia Therapeutics, Inc. ( NASDAQ:NTLA ), given that the company...Analysis Article • Feb 24
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) shareholders are probably feeling a little disappointed, since its shares...Recent updates
New Narrative • Sep 08
Single-Treatment Gene Editing Will Likely Limit Recurring Demand And Pressure Long-Term Earnings
Catalysts About Intellia Therapeutics Intellia Therapeutics develops in vivo CRISPR gene editing therapies, including potential onetime treatments for hereditary angioedema and transthyretin amyloidosis. What are the underlying business or industry changes driving this perspective?
Narrative Update • Aug 22
NTLA: Future CRISPR Readouts And Resumed ATTR Trials Could Reframe Upside Potential
Intellia Therapeutics' updated analyst price target has been revised in light of mixed recent research, with some analysts lifting targets as high as $24 on increased confidence in its nex-z program, while others remain cautious with targets closer to $9 due to cash and execution concerns. Analyst Commentary Recent research around Intellia Therapeutics reflects a split view, but bullish analysts see meaningful upside potential tied to its nex-z program and the latest clinical and competitive updates.Analysis Article • Aug 10
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported And Analysts Have Been Cutting Their Estimates
It's been a pretty great week for Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) shareholders, with its shares surging 11...
Narrative Update • Aug 07
NTLA: Late Stage Gene Editing Progress And FDA Milestones Will Drive Upside
Analysts now place Intellia Therapeutics' fair value closer to $23.94 from about $26.63, reflecting updated assumptions that include a higher discount rate, more moderate revenue growth, stronger profit margin expectations, and a lower future P/E multiple in light of recent shifts in Street price targets and clinical risk views. Analyst Commentary Recent Street views on Intellia Therapeutics show a split between analysts who focus on its clinical positioning and those who concentrate on funding needs and commercial timing.Seeking Alpha • Jul 29
Intellia: Phase 3 HAELO Win Doesn't Fix The Commercial Problem
Summary Intellia Therapeutics remains a 'Sell' despite positive Phase 3 HAELO results for lonvo-z in hereditary angioedema. Lonvo-z matched or exceeded current HAE therapies in efficacy and safety, but commercial uptake is expected to be slow without long-term data. NTLA's peak HAE market share is estimated at just 4%, reflecting patient hesitancy for one-time gene edits over established, reversible treatments. Persistent high cash burn, dilution risk, and limited commercial prospects outside HAE constrain NTLA’s valuation and investment appeal. Read the full article on Seeking AlphaNarrative Update • Jun 23
NTLA: Phase 3 Gene Editing Readouts And FDA Progress Will Drive Upside
Analysts have lifted their price target on Intellia Therapeutics to $17 from $13, reflecting updated views on the company in the context of a stronger biotech sector and expectations for continued merger-and-acquisition and IPO activity. Analyst Commentary Recent moves around Intellia Therapeutics show a mix of optimism and caution, with several firms revisiting their models and adjusting price targets in both directions as they reassess sector conditions and company specific execution risk.Analysis Article • Jun 19
Intellia Therapeutics (NTLA) Stock Could Be 41.2% Undervalued After Phase 3 HAE Data
Intellia Therapeutics (NTLA) is back in focus after releasing detailed Phase 3 HAELO trial data for its CRISPR-based therapy lonvo-z in hereditary angioedema, alongside a rolling biologics license application with the FDA. See our latest analysis for Intellia Therapeutics. The latest HAELO data and rolling BLA have coincided with a sharp shift in sentiment toward Intellia Therapeutics, with a 7 day share price return of 29.40% and a year to date share price return of 70.14%, set against a 3...Narrative Update • Jun 06
NTLA: Phase 3 HAE Progress And FDA Momentum Will Drive Future Upside
Analysts have nudged Intellia Therapeutics' updated price target slightly lower to $26.63 from $26.70, reflecting adjusted assumptions on revenue growth, profit margins and future P/E while incorporating a recent mix of upward and downward target revisions across the Street. Analyst Commentary Recent research on Intellia Therapeutics reflects a mix of optimism and caution, with several firms adjusting price targets in both directions and reassessing the companys execution and risk profile.Narrative Update • May 14
NTLA: Clinical Hold Resolution Will Reopen ATTR Phase 3 Upside Potential
Analysts have lifted the fair value estimate for Intellia Therapeutics to $26.70 from $25.29. This reflects a series of higher price targets across the Street as recent FDA decisions on the MAGNITUDE program ease regulatory concerns and support more optimistic assumptions on revenue growth, profitability, and long-term P/E potential.Analysis Article • May 14
Earnings Update: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) defied analyst predictions to release its quarterly results, which were...Narrative Update • Apr 26
NTLA: Clinical Hold Resolution Will Reopen Key ATTR Phase 3 Catalyst
Narrative Update The analyst price target for Intellia Therapeutics is now set at $25.29. Analysts point to the FDA lifting clinical holds on the MAGNITUDE studies, the resumption of Phase 3 enrollment for nexiguran ziclumeran, and updated trial protocols as key reasons for their revised views.Narrative Update • Apr 11
NTLA: Clinical Hold Resolution Will Restore ATTR Phase 3 Value Driver
Analysts moved Intellia Therapeutics' consolidated price target higher toward the mid to high $20s, citing the FDA's decision to lift clinical holds on the MAGNITUDE programs for nexiguran ziclumeran and noting that the updated safety protocols support the continuation of Phase 3 enrollment. Analyst Commentary Recent Street research highlights a clear shift in sentiment around Intellia Therapeutics following the FDA decision to lift clinical holds on the MAGNITUDE programs and allow Phase 3 enrollment to resume under updated safety protocols.Narrative Update • Mar 27
NTLA: Clinical Hold Resolution Will Reopen ATTR Phase 3 Value Opportunity
Analysts lifted their price targets on Intellia Therapeutics toward a range of about $15 to $48 after the FDA removed clinical holds on the MAGNITUDE program, citing improved clarity on safety, updated trial protocols, and a higher assumed probability of success for nexiguran ziclumeran in ATTR indications. Analyst Commentary Research updates following the FDA's decision cluster around how much value investors should assign to nexiguran ziclumeran in transthyretin amyloidosis and how execution risk in Phase 3 might affect Intellia Therapeutics' longer term profile.Narrative Update • Mar 12
NTLA: Clinical Hold Resolution Will Restore Confidence In ATTR Phase 3 Franchise
Analysts have raised their blended price target for Intellia Therapeutics from $23.86 to $25.29, citing the FDA's removal of clinical holds on MAGNITUDE studies and renewed confidence in the nex-z program as key reasons for the change. Analyst Commentary Recent research commentary on Intellia Therapeutics clusters around the FDA decision to lift clinical holds on the MAGNITUDE and MAGNITUDE 2 programs for nexiguran ziclumeran, with most firms updating price targets and ratings in response.Narrative Update • Feb 25
NTLA: Nex Z Clinical Return Will Ease ATTR Concerns And Support Repricing
Narrative Update on Intellia Therapeutics The analyst price target for Intellia Therapeutics has been raised, with recent moves such as Baird lifting its target to $7 and H.C. Wainwright increasing its target by $10, as analysts point to progress on nex-z returning to the clinic and a broader reassessment of U.S. biopharma valuations. Analyst Commentary Recent Street research on Intellia Therapeutics reflects a mix of optimism tied to specific catalysts and caution around broader sector risks and execution.Narrative Update • Feb 09
NTLA: Nex Z Return To Clinic Will Offset ATTR Safety Overhang
Analysts have lifted their fair value estimate for Intellia Therapeutics by about $1.58 per share, supported by recent price target increases from firms citing potential value from a nex-z return to clinic, even as others trim or withdraw targets on safety concerns and a higher assumed future P/E of about 45.5x. Analyst Commentary Recent Street research on Intellia Therapeutics reflects a split view, with some analysts focusing on potential value creation from a nex z return to clinic and others centering on safety concerns and a narrower path to upside.New Narrative • Feb 02
One Time Genetic Medicines And Late Stage Pipeline Will Redefine Long Term Potential
Catalysts About Intellia Therapeutics Intellia Therapeutics develops CRISPR based genetic medicines aimed at one time treatments for serious diseases. What are the underlying business or industry changes driving this perspective?Narrative Update • Jan 24
NTLA: Hereditary Angioedema Progress Will Offset ATTR Liver Safety Concerns
Analysts have trimmed their price targets on Intellia Therapeutics across the board, with several cuts into the single to low double digit US$ range. They are reassessing the risk profile of the ATTR cardiomyopathy program following serious liver toxicity events and related trial pauses and holds.Narrative Update • Jan 10
NTLA: Hereditary Angioedema Data Will Drive Future Upside Despite Liver Safety Hold
Intellia Therapeutics' updated analyst price target edges slightly lower as analysts factor in recent safety driven downgrades and target cuts, reflected in a modest reduction in fair value to about $22.27 and a slightly lower forward P/E assumption of roughly 42x. Analyst Commentary Recent Street research on Intellia Therapeutics clusters around the safety questions raised in its ATTR cardiomyopathy program and how those issues flow through to valuation, probability of approval assumptions, and perceived execution risk across the broader platform.Narrative Update • Dec 25
NTLA: Hereditary Angioedema Franchise Will Drive Future Upside Despite Ongoing Liver Safety Overhang
Analysts have modestly reduced their average price target on Intellia Therapeutics, trimming fair value by low single digits to around $22 per share, as mounting safety concerns and FDA holds around nexiguran ziclumeran narrow the perceived risk or reward profile despite some lingering optimism on the broader pipeline. Analyst Commentary Street research has turned more cautious on Intellia following the liver safety events in the transthyretin-mediated amyloidosis program, with multiple downgrades and target cuts reflecting a reassessment of risk, probability of approval, and the contribution of nexiguran ziclumeran to long term growth.Narrative Update • Dec 10
NTLA: Hereditary Angioedema Program Will Drive Future Upside Despite ATTR Safety Overhang
Analysts have modestly reduced their average price target on Intellia Therapeutics, trimming projected upside by a few dollars per share as mounting liver safety concerns around nexiguran ziclumeran, multiple downgrades, and lowered probability of approval assumptions for the ATTR program weigh more heavily against otherwise intact long term gene editing optionality and the opportunity in hereditary angioedema. Analyst Commentary Street research has turned more cautious on Intellia in the near term, with multiple downgrades and target cuts reflecting heightened uncertainty around the ATTR program and the broader platform safety profile, even as some analysts still highlight long term value in gene editing and the hereditary angioedema franchise.Narrative Update • Nov 26
NTLA: Positive Phase 3 Data And Upcoming Regulatory Filing Will Drive Future Upside
Analysts have lowered their average price target on Intellia Therapeutics from approximately $24.85 to $22.43 per share. They cited heightened safety concerns related to recent clinical trial liver toxicity events and uncertainty about the future of key pipeline programs.Narrative Update • Nov 12
NTLA: Phase 3 Enrollment Milestones And Data Readouts Will Drive Next Upside
Analysts have reduced their fair value estimate for Intellia Therapeutics from approximately $32.30 to $24.85. They cite heightened safety concerns in key clinical programs and lower projected growth rates following recent adverse events and subsequent trial pauses.Narrative Update • Oct 29
Paused Trials Will Drive Rebound After Resolution Of Safety Concerns
Intellia Therapeutics' consensus price target has declined from approximately $34.08 to $32.30 per share. Analysts cite heightened safety concerns surrounding recent liver injury events and paused clinical trials as key drivers behind lower valuation estimates.Analysis Article • Sep 18
Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Narrative Update • Aug 10
Robust In Vivo CRISPR Trials Will Accelerate Therapeutic Success
Despite a notable improvement in both future P/E and net profit margin, Intellia Therapeutics’ consensus analyst price target has been revised downward from $37.11 to $35.23. What's in the News Phase 3 HAELO trial for lonvo-z in hereditary angioedema (HAE) is ongoing, showing strong interim efficacy data; drug has received multiple regulatory designations, including FDA Orphan Drug and RMAT.Analysis Article • May 11
Analysts Have Made A Financial Statement On Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) First-Quarter Report
A week ago, Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) came out with a strong set of first-quarter numbers that could...Analysis Article • May 10
Industry Analysts Just Made An Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts
Celebrations may be in order for Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) shareholders, with the analysts delivering...
New Narrative • Mar 25
Phase III Trials And Gene Editing Will Bring Promising Therapies
Strategic discontinuation of less promising programs and capital prioritization are expected to improve net margins and enhance commercial prospects.Seeking Alpha • Mar 02
Intellia Trades Lower After Q4 Results As Clinical Progress Fails To Impress
Summary Intellia Therapeutics' stock is downgraded to HOLD due to market skepticism and lack of near-term catalysts despite promising Phase 3 trials for HAE and ATTR. NTLA-2002, Intellia's CRISPR/Cas9 drug for HAE, is the closest to commercialization, expected by 2027, but profitability remains distant. Intellia's financials show a cash runway extended through 2027, but additional funding or partnerships will likely be needed for profitability. Gene therapy sector uncertainty, exemplified by bluebird bio's struggles, underscores the risks and potential rewards for Intellia investors willing to wait. Read the full article on Seeking AlphaAnalysis Article • Mar 02
Earnings Release: Here's Why Analysts Cut Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Price Target To US$46.08
Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) defied analyst predictions to release its yearly results, which were ahead...Analysis Article • Feb 15
Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Jan 13
Intellia Therapeutics: Buying The Path To Commercialization
Summary Intellia Therapeutics, Inc. is undergoing strategic reorganization, halting NTLA-3001, and reducing workforce by 27% to extend cash runway into 2027, focusing on late-stage programs NTLA-2002 and Nexiguran Ziclumeran. Despite industry headwinds and significant layoffs, I see Intellia's cost-cutting measures as prudent, aiming for commercialization of NTLA-2001 and NTLA-2002 in large, promising markets. The gene therapy sector faces turmoil, with multiple companies making tough decisions; however, Intellia's focus on late-stage programs may position it for future growth and potential M&A interest. I initiated a speculative buy on NTLA under $10 per share, anticipating a potential technical rebound and long-term investment opportunities as the company approaches commercialization. Read the full article on Seeking AlphaSeeking Alpha • Nov 19
Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
Summary Intellia initiated the Phase 3 HAELO trial for NTLA-2002, targeting lifelong control of hereditary angioedema (HAE) with a single-dose CRISPR-based therapy. Positive Phase 2 NTLA-2002 data showed most patients remained attack-free; however, limitations like small sample size and short follow-up require cautious interpretation. Phase 1 data for nexiguran ziclumeran (nex-z) in ATTR amyloidosis showed disease stabilization, but competitive therapies demonstrate more robust improvements. Intellia has strong financial health, with over $900M in liquidity and a cash runway expected to last until late 2026. Intellia's limited transformational data, high manufacturing costs, and competitive landscape justify downgrading the stock from "Buy" to "Hold." Read the full article on Seeking AlphaSeeking Alpha • Nov 11
Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus
Summary Intellia Therapeutics' NTLA-2002 Phase II results last month were underwhelming, however, management reassured investors on the Q3 earnings call setting the stage for a modest rally. While last month's drop is appropriately discounting NTLA-2002, investors should be encouraged that 3 Phase III trials will be engaged by year-end, representing multiple opportunities for substantial upside. Intellia's financial position is robust with $945 million in cash, enough to fund operations into late 2026. NTLA-2002's Phase III study will enroll 60 patients and is anticipated to reach its primary endpoint by April 2026, potentially offering a functional cure for hereditary angioedema (HAE). HAE represents a huge market opportunity estimated to reach $17.4 billion by 2032. Read the full article on Seeking AlphaSeeking Alpha • Nov 05
Data Underwhelms - Intellia's Cash, Data And Competition Are A Challenging Story
Summary ATTR has become a more competitive space, with uncertainty ahead on Phase III timelines. Recent data on HAE did not provide a differentiated outcome from more advanced competitors. The competitive landscape across lead indications is evolving rapidly and may create unforeseen challenges to trial completion or commercialization. Funding and regular share offerings are diminishing flexibility and potential return for investors. 2026 cash runway may be insufficient to obtain meaningful Phase III clinical readouts. Read the full article on Seeking AlphaSeeking Alpha • Oct 25
Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity
Summary Intellia Therapeutics, Inc. achieved positive phase 1/2 results using NTLA-2002 for HAE patients: 8 out of 11 patients taking higher doses of 50 mg of NTLA-2002 were attack-free during the 16-week primary observation period. Despite the stock price trading lower by 20%, the HAE treatment program continues on using NTLA-2002 in the phase 3 HAELO study. The global hereditary angioedema treatment market size is projected to reach $17.31 billion by the end of 2032. NTLA-2001 is another in vivo CRISPR drug being developed to target patients with transthyretin [ATTR] amyloidosis being explored in the phase 3 MAGNITUDE study; Updated phase 1 data is expected 2nd half of 2024. Read the full article on Seeking AlphaSeeking Alpha • Sep 25
Intellia - Exciting Promise Of First In-Vivo Gene Therapy Makes Bull Case
Summary Intellia Therapeutics is pioneering in-vivo CRISPR gene editing, aiming for groundbreaking therapies, with NTLA-2001 showing promising results in ATTR amyloidosis, potentially achieving blockbuster status. Despite a 65% stock drop since 2022, Intellia's advancements in Phase 3 trials and strong partnerships, like with Regeneron, make it a compelling buy opportunity. The company's innovative use of lipid nanoparticles for gene delivery and a robust pipeline position it as a leader in the CRISPR space, targeting large markets. With a cash position of $940m and multiple Phase 3 studies in play, Intellia is poised for substantial valuation growth and a possible Big Pharma acquisition. The major risks to the thesis are a safety setback or a failure to deliver on approval-worthy efficacy endpoints, but this is mitigated somewhat by the success of e.g. Crispr Therapeutics / Vertex very effective sickle cell disease therapy Casgevy. Read the full article on Seeking AlphaAnalysis Article • Sep 07
We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analysis Article • Aug 11
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
The analysts might have been a bit too bullish on Intellia Therapeutics, Inc. ( NASDAQ:NTLA ), given that the company...Seeking Alpha • Aug 03
Intellia Therapeutics Is Expanding The Scope Of Gene Editing (Technical Analysis)
Summary The future is here… The CRISPR-Cas9 gene editing platform lets us reshuffle DNA, analogous to how we edit text. The difference is that CRISPR-Cas9 is a much more powerful tool that we’re slowly learning to use. It’s important that we master it… gene editing is the best treatment for many serious diseases. Intellia Therapeutics is blazing new trails in using CRISPR-Cas9 to treat more conditions. But we can’t compute any sort of valuation for the stock, so it’s only suitable as a sentiment play. Read the full article on Seeking AlphaAnalysis Article • Jun 06
Here's Why It's Unlikely That Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO Will See A Pay Rise This Year
Key Insights Intellia Therapeutics will host its Annual General Meeting on 12th of June Total pay for CEO John Leonard...Seeking Alpha • Jun 05
Intellia Therapeutics Presents Promising In Vivo CRISPR Results
Summary Intellia Therapeutics has released positive data from its Phase I/II study of NTLA-2002, a CRISPR-based gene editing therapy. The study shows promising results for in vivo gene editing, offering potential treatments for genetic diseases. Robust target engagement and efficacy data pave the way for future Phase II results from Intellia later this year. Intellia has the most advanced in vivo gene editing portfolio, which, while speculative, could represent a huge advance for the field in coming years. Read the full article on Seeking AlphaAnalysis Article • May 14
Industry Analysts Just Made A Dazzling Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts
Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) shareholders will have a reason to smile today, with the analysts making...Seeking Alpha • May 13
Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies
Summary Intellia's longstanding collaboration with Regeneron is important in its value proposition. With three cutting-edge late-stage programs, NTLA is among the top tier of gene editing companies. Solid financials underpin the Company. Intellia presents special risks. Read the full article on Seeking AlphaSeeking Alpha • Feb 29
Intellia Therapeutics Is On The Move
Summary Today, we circle back on gene editing concern Intellia Therapeutics, Inc., whose stock has moved up by a third over the past month. The company has potential cures for HAE and ATTR-CM within its pipeline, but commercialization is years away. An updated analysis around Intellia Therapeutics follows in the paragraphs below. Read the full article on Seeking AlphaAnalysis Article • Feb 24
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) shareholders are probably feeling a little disappointed, since its shares...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 372 | -233 | -306 | -403 | 12 |
| 12/31/2027 | 126 | -374 | -367 | -391 | 17 |
| 12/31/2026 | 52 | -420 | -404 | -351 | 17 |
| 6/30/2026 | 60 | -400 | -349 | -347 | N/A |
| 3/31/2026 | 66 | -395 | -364 | -363 | N/A |
| 12/31/2025 | 68 | -413 | -396 | -395 | N/A |
| 9/30/2025 | 58 | -446 | -413 | -411 | N/A |
| 6/30/2025 | 53 | -480 | -422 | -419 | N/A |
| 3/31/2025 | 46 | -526 | -381 | -377 | N/A |
| 12/31/2024 | 58 | -519 | -355 | -349 | N/A |
| 9/30/2024 | 43 | -522 | -363 | -357 | N/A |
| 6/30/2024 | 46 | -509 | -383 | -373 | N/A |
| 3/31/2024 | 53 | -486 | -418 | -405 | N/A |
| 12/31/2023 | 36 | -481 | -408 | -394 | N/A |
| 9/30/2023 | 52 | -462 | -407 | -391 | N/A |
| 6/30/2023 | 53 | -453 | -384 | -368 | N/A |
| 3/31/2023 | 53 | -430 | -379 | -363 | N/A |
| 12/31/2022 | 52 | -474 | -392 | -333 | N/A |
| 9/30/2022 | 51 | -442 | -355 | -298 | N/A |
| 6/30/2022 | 45 | -400 | -342 | -285 | N/A |
| 3/31/2022 | 38 | -369 | -309 | -252 | N/A |
| 12/31/2021 | 33 | -268 | -238 | -225 | N/A |
| 9/30/2021 | 27 | -229 | -221 | -211 | N/A |
| 6/30/2021 | 42 | -185 | -181 | -174 | N/A |
| 3/31/2021 | 52 | -149 | -69 | -64 | N/A |
| 12/31/2020 | 58 | -134 | -53 | -50 | N/A |
| 9/30/2020 | 62 | -120 | -43 | -38 | N/A |
| 6/30/2020 | 51 | -116 | -41 | -35 | N/A |
| 3/31/2020 | 46 | -109 | N/A | -120 | N/A |
| 12/31/2019 | 43 | -100 | N/A | -103 | N/A |
| 9/30/2019 | 40 | -90 | N/A | -83 | N/A |
| 6/30/2019 | 37 | -89 | N/A | -70 | N/A |
| 3/31/2019 | 33 | -86 | N/A | -65 | N/A |
| 12/31/2018 | 30 | -85 | N/A | -61 | N/A |
| 9/30/2018 | 29 | -90 | N/A | -74 | N/A |
| 6/30/2018 | 29 | -83 | N/A | -78 | N/A |
| 3/31/2018 | 27 | -76 | N/A | -72 | N/A |
| 12/31/2017 | 26 | -68 | N/A | -65 | N/A |
| 9/30/2017 | 25 | -54 | N/A | -58 | N/A |
| 6/30/2017 | 23 | -46 | N/A | -49 | N/A |
| 3/31/2017 | 21 | -38 | N/A | 34 | N/A |
| 12/31/2016 | 16 | -32 | N/A | 36 | N/A |
| 9/30/2016 | 13 | -26 | N/A | 45 | N/A |
| 6/30/2016 | 9 | -22 | N/A | 49 | N/A |
| 3/31/2016 | 7 | -18 | N/A | -16 | N/A |
| 12/31/2015 | 6 | -12 | N/A | -2 | N/A |
| 9/30/2015 | 4 | -14 | N/A | 1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NTLA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NTLA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NTLA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NTLA's revenue (58.7% per year) is forecast to grow faster than the US market (13.4% per year).
High Growth Revenue: NTLA's revenue (58.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NTLA's Return on Equity is forecast to be low in 3 years time (6.6%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 23:35 |
| End of Day Share Price | 2026/09/14 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Intellia Therapeutics, Inc. is covered by 31 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Brian Skorney | Baird |
| Alec Stranahan | BofA Global Research |